Transgene SA has signed agreements giving its Chinese joint venture partner Tasly Biopharmaceuticals Co., Ltd. rights in Greater China to T601 and T101, two immunotherapeutics already under development by the companies' equally owned JV, full ownership of which will also be turned over to Tasly as part of the deal.
Tasly Gains Products As Transgene Sells Up China JV Stake
Transgene is divesting its Chinese joint venture to local partner Tasly, which is also acquiring selected rights to two Transgene products ahead of a planned IPO, in deal that will see the French firm net close to $50m in stock.
